Showing results (671-680 of 1,155) with videos related to

Sort By:
Pageof 116
The American Journal of Sports Medicine|October 17, 2025
Revision Hip Arthroscopy: Identifying Indications and Outcomes With a Mean 5-Year Follow-upRyan S Selley, Hayden P Baker, Joost A Burger, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1975
Diversion of peripheral thyroxine metabolism from activating to inactivating pathways during complete fastingA G Vagenakis, A Burger, G I Portnary, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|April 29, 2020
Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic AneurysmsLars Husmann, Martin W Huellner, Bruno Ledergerber, et al.
Cancer Research|June 30, 2001
A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11M M Meck, M Wierdl, L M Wagner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes?Alexander Maurer, Urs J Muehlematter, Thibika Sivakumar, et al.
European Radiology|May 9, 2013
Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenterationOlivio F Donati, Yulia Lakhman, Evis Sala, et al.
BMC Medicine|February 6, 2016
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trialsPatrick P J Phillips, Carl M Mendel, Divan A Burger, et al.
Journal of the National Cancer Institute|October 24, 2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker AnalysesCarlos Bais, Barbara Mueller, Mark F Brady, et al.
Cancers|January 21, 2023
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 StudyJennifer A Woyach, Paul M Barr, Thomas J Kipps, et al.
Journal of the National Cancer Institute. Monographs|November 12, 2024
Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modelingMarc Brisson, Jean-François Laprise, Mélanie Drolet, et al.
Pageof 116